NID1 and neoplasm: We have previously reported a tumor extracellular matrix (ECM)-targeting peptide, CSG, that specifically binds to the aberrant network of laminin-nidogen-1 complex in a number of mouse and human solid tumors including breast, pancreatic and liver cancers (5).